These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7885050)

  • 21. Coexisting myelodysplasia and myeloproliferative features in a single clone containing 5q-, Ph and i(17q).
    Garay CA; Al-Saleem T; Testa JR; Smith MR
    Leuk Res; 1999 Oct; 23(10):965-7. PubMed ID: 10573144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The 5q(-) syndrome. Report of 2 cases].
    Ben Lakhal R; Meddeb B; Gouider E; Aissaoui L; Sannana Sandi H; Ben Abid H; Belhaj Ali Z; Hafsia R; Hafsia A
    Tunis Med; 1999 Nov; 77(11):589-92. PubMed ID: 10730148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA; Germing U; Aul C
    Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An uncommon case of a child with del(5q) and hypocellular myelodysplastic syndrome.
    de Souza DC; Otero L; Tavares Rde C; Dobbin J; Abdelhay E; Fernandez Tde S
    Pediatr Blood Cancer; 2010 Oct; 55(4):767. PubMed ID: 20589660
    [No Abstract]   [Full Text] [Related]  

  • 25. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic abnormalities in the myelodysplastic syndrome.
    Jacobs A
    Acta Haematol Pol; 1991; 22(2):197-202. PubMed ID: 1841492
    [No Abstract]   [Full Text] [Related]  

  • 27. Revealing the pathogenesis of the 5q- syndrome.
    Valent P
    Eur J Clin Invest; 2008 Aug; 38(8):539-40. PubMed ID: 18717823
    [No Abstract]   [Full Text] [Related]  

  • 28. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
    Terpos E; Verrou E; Banti A; Kaloutsi V; Lazaridou A; Zervas K
    Leuk Res; 2007 Apr; 31(4):559-62. PubMed ID: 16820206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haematopoietic cytokines and increased megakaryocytic proliferation in chromosome 5q deletion.
    Haznedaroğlu IC; Ozcebe OI; Dündar SV; Kirazli S
    Acta Haematol; 1997; 97(4):244. PubMed ID: 9158672
    [No Abstract]   [Full Text] [Related]  

  • 32. [Analysis the clinic and cytogenetics of myelodysplastic syndrome].
    Cen L; Zhou M; Zhao YH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):668-9. PubMed ID: 17160950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
    J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic survey of sixty-one patients with preleukemic syndrome including myeloproliferative and myelodysplastic diseases.
    Palka G; Spadano A; Calabrese G; Parruti G; Guanciali Franchi P; Di Sante O; Recchia A; Di Lorenzo R; Torlontano G
    Ann Genet; 1990; 33(4):214-8. PubMed ID: 2095702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review.
    Panani AD; Pappa V; Papageorgiou S; Stamatelli F; Raptis SA
    Ann Hematol; 2004 Mar; 83(3):153-5. PubMed ID: 15064863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion.
    Stavropoulou C; Sambani C; Rigana H; Georgakakos VN; Voutsinas G; Manola KN; Pantelias GE; Makropoulos V;
    Leukemia; 2008 Aug; 22(8):1643-6. PubMed ID: 18305556
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
    Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5q-: does longer survival of female patients explain the preponderance.
    Pedersen B
    Anticancer Res; 1997; 17(5A):3281-5. PubMed ID: 9413160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.